Following the manufacturing and marketing approval from DCGI, Hetero is launching remdesivir under the brand COVIFOR in India.
The company secured approval for suspected or laboratory-confirmed Covid-19 cases in hospitalised adults and children. Hetero Group of Companies chairman Partha Saradhi Reddy said: “In the light of increasing Covid-19 cases in India, the approval of ‘COVIFOR’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes. What do you see as the main benefit of telemedicine?View Results“We are prepared for ensuring enough stocks required to cater to the present needs.
Read more on pharmaceutical-technology.com